ClinicalTrials.gg
CompletedNCT02289352Updated Jan 14, 2020Results posted

Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea

A Phase 3 interventional study of Brimonidine and placebo in Rosacea, sponsored by Actavis Inc.. Completed at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-14.

Sponsored by Actavis Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
462
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing brimonidine in Rosacea — none open to participants now, none under way, none of them phase 3. brimonidine · Rosacea.

Enrollment
Largest of 11
462 · median 205
Started
2014
with 1 other
Phase 3
4 of 11
none open now
Registered
8th of 11
by date
Lead sponsor
1 of 11
Actavis Inc.

Among the 11 studies testing brimonidine in Rosacea, this one has the largest enrollment, is one of 2 that started in 2014, is one of 4 in phase 3, and was the 8th registered.

Rosacea

233 studies on the registry are indexed under Rosacea; 23 are open to participants now.

Browse Rosacea studies →

Open to participants now

None of the 11 studies testing brimonidine in Rosacea is open now. The open studies under Rosacea, anywhere →

Where they have run

About brimonidine

brimonidine: first FDA approval 1996 (ALPHAGAN), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 17 Rosacea studies recruiting now, 9 (53%) set no upper age limit and 7 (41%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing brimonidine in Rosacea as a file.
02

Study summary

A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety and Therapeutic Equivalence of Brimonidine Topical Gel, 0.33% (Watson Laboratories, Inc., USA) to Reference Product Mirvaso® (brimonidine) topical gel, 0.33% (Galderma Laboratories, L.P., USA) in Patients with Moderate to Severe Facial Erythema Associated with Rosacea

Read the detailed description

Up to 462 patients 18 years of age and older, with confirmed clinical diagnosis of rosacea will be enrolled to have 413 in the modified intent-to-treat (mITT) population and 371 in the per-protocol (PP) population. Patients should have fewer than 3 facial inflammatory lesions, and moderate to severe erythema according to both Clinician's Erythema Assessment (CEA) and Patient's Self-Assessment (PSA).

03

Conditions studied

  • Rosacea

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or non-pregnant, non-lactating female, 18 years of age or older.
  2. Signed form, which meets all criteria of current FDA regulations.
  3. Females of child bearing potential must not be pregnant or lactating at Screening and Randomization (as confirmed by a negative urine pregnancy test with a sensitivity of less than 25 mlU/mL or equivalent units of human chorionic gonadotropin). Women of must agree to the use of a reliable method of (e.g., total abstinence, IUD, a double-barrier method [such as condom plus diaphragm with spermicide], oral, transdermal, injected or implanted non- or hormonal contraceptive), throughout the study. A sterile sexual partner is not considered an adequate form of birth control.

    All females will be considered to be of childbearing potential unless they:

    • Are , defined as women who have been amenorrheic for at least 12 consecutive months, without other known or suspected primary cause.
    • Have been sterilized surgically or who are otherwise proven sterile (i.e., total hysterectomy, or bilateral oophorectomy) with surgery at least 4 weeks prior to Screening. Tubal ligation will not be considered a surgically sterile method.

    Female patients of childbearing potential are defined as:

    • Women without prior hysterectomy, or who have had any evidence of menses in the past 12 months.
    • Females who have been amenorrhea for ≥ 12 months, but the amenorrhea is possibly due to other causes, including prior chemotherapy, anti-estrogens, or ovarian suppression.
  4. Have a clinical diagnosis of facial rosacea and fewer than 3 inflammatory lesions on the face at Screening and at Randomization (before drug application on Day 1).
  5. Have moderate to severe facial erythema according to both CEA and PSA (i.e., an erythema score of 3 or more for each of the CEA and PSA) at Screening and at Randomization (before drug application on Day 1).
  6. Free from any systemic or dermatologic disorder (other than rosacea) that, in the opinion of the Investigator, will interfere with the study evaluations or increase the risk of AEs.
  7. Willing to minimize external factors that might trigger rosacea flare-ups (e.g., hot environments, prolonged sun exposure, strong winds and emotional stress) within 24 hours of the Screening and Randomization visit.
  8. Any skin type or race, providing the skin pigmentation will allow discernment of erythema.
  9. Willingness and capability to cooperate to the extent and degree required by the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Patients with particular forms of rosacea (rosacea conglobata, rosacea fulminans, isolated rhinophyma, isolated pustulosis of the chin) or other concomitant facial dermatoses similar to rosacea, such as peri-oral dermatitis, demodicidosis, facial keratosis pilaris, seborrheic dermatitis, acute lupus erythematosus, or actinic telangiectasia, that are present on the face (i.e., 5 areas: chin, nose, both cheeks, and forehead), that in the opinion of the Investigator would interfere with study evaluations.
  2. Have 3 or more facial inflammatory lesions of rosacea.
  3. Have an erythema score of 2 (mild), 1 (almost clear), or 0 (clear) on the CEA and/or the PSA at Screening and at Randomization (before drug application on Day 1).
  4. Patients with excessive facial hair (beards, sideburns, mustaches, etc.) that would interfere with the diagnosis or assessment of rosacea.
  5. Patients with moderate to severe telangiectasial masses in the 5 areas of the entire face: forehead, chin, nose and each cheek, that would interfere with study evaluations.
  6. History of or allergy to Mirvaso® including the active ingredient brimonidine tartarate or other component within the formulation.
  7. Facial laser surgery for telangiectasia (or other conditions) within 6 weeks prior to randomization.
  8. Exposed to excessive ultraviolet (UV) radiation within 1 week before screening or randomization visit and/or patient was unwilling to refrain from excessive exposure to UV radiation during the course of the study.
  9. History of blood dyscrasia.
  10. Current diagnosis of Raynaud's syndrome, thromboangiitis obliterans, orthostatic hypotension, severe cardiovascular disease, cerebral or coronary insufficiency, renal or hepatic impairment, scleroderma, Sjögren's syndrome, or depression, or any other condition causing uncontrolled blood flow or blood pressure.
  11. Females who are pregnant, lactating or likely to become pregnant during the study.
  12. Significant history or current evidence of chronic infectious disease, system disorder, organ disorder or other medical condition that in the Investigator's opinion would place the study patient at undue risk by participation.
  13. Patients with severe, unstable or uncontrolled cardiovascular disease.
  14. Patients who meet study restrictions at Screening and Randomization and/or unwillingness to comply with all restricted treatments
  15. Receipt of any drug as part of a research study within 30 days before dosing.
  16. Employees of the research center or Investigator.
  17. Previous participation in this study.
  18. Patients who are unable and/or unwilling to follow the study requirements, and procedures.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
462 participants (actual)

Study arms

  • Experimental
    brimonidine 0.33% gel

    Brimonidine Topical Gel, 0.33%, 30 gram fill (Watson Laboratories, Inc., USA)

    Drug: Brimonidine

  • Active comparator
    Mirvaso gel

    Mirvaso® (brimonidine) topical gel, 0.33% (Galderma Laboratories, L.P., USA)

    Drug: Brimonidine

  • Placebo comparator
    Placebo

    Topical gel base only (Watson Laboratories Inc., USA)

    Drug: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Primary: Percentage of Treatment Success on Day 7

    Percentage of patients with a clinical response of treatment success on Day 7 (± 1). Treatment success is defined as at least a 2-grade improvement on both CEA and PSA scores from baseline (pre-dose) on Day 7 (± 1) to 6 hours post-application on Day 7 (± 1).

    Time frame: 7 days

Secondary outcomes

  1. Percentage of Patients With a Clinical Response of Treatment Success on Day 1

    Time frame: 1 day

07

Results

Posted Jan 14, 2020

Participant flow

Participant flow — Overall Study
MilestoneTest: Brimonidine 0.33% GelReference: Mirvaso 0.33% GelPlacebo Gel Vehicle
Started19919964
Safety population19919964
Mitt population19119358
Pp population17317354
Completed19819864
Not completed110
Withdrew: Withdrawal by subject110

Outcome measures

PrimaryPrimary: Percentage of Treatment Success on Day 7

Percentage of patients with a clinical response of treatment success on Day 7 (± 1). Treatment success is defined as at least a 2-grade improvement on both CEA and PSA scores from baseline (pre-dose) on Day 7 (± 1) to 6 hours post-application on Day 7 (± 1).

Time frame:
7 days
Reported as:
Number · percentage of participants
Primary: Percentage of Treatment Success on Day 7
percentage of participantsTest: Brimonidine 0.33% GelReference: Mirvaso 0.33% GelPlacebo
Primary: Percentage of Treatment Success on Day 79.9510.360
Statistical analysis
  • Test: Brimonidine 0.33% Gel vs Reference: Mirvaso 0.33% Gel · Mean difference (net): -0.58 · 90% CI -6.49 to 5.33
  • Test: Brimonidine 0.33% Gel vs Placebo · t-test, 2 sided · p = <0.0001
  • Reference: Mirvaso 0.33% Gel vs Placebo · t-test, 2 sided · p = <0.0001
SecondaryPercentage of Patients With a Clinical Response of Treatment Success on Day 1
Time frame:
1 day
Reported as:
Number · percentage of participants
Percentage of Patients With a Clinical Response of Treatment Success on Day 1
percentage of participantsTest: Brimonidine 0.33% GelReference: Mirvaso 0.33% GelPlacebo
Percentage of Patients With a Clinical Response of Treatment Success on Day 130.8930.898.62
Statistical analysis
  • Test: Brimonidine 0.33% Gel vs Reference: Mirvaso 0.33% Gel · Mean difference (net): 6.94 · 90% CI -1.54 to 15.41
  • Test: Brimonidine 0.33% Gel vs Placebo · t-test, 2 sided · p = <0.0001
  • Reference: Mirvaso 0.33% Gel vs Placebo · t-test, 2 sided · p = 0.0045

Adverse events

Collected over Baseline to Day 7. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Test:Brimonidine 0.33% Gel26/199 (13.1%)0/199 (0%)26/199 (13.1%)
Reference: Mirvaso 0.33% Gel22/199 (11.1%)0/199 (0%)22/199 (11.1%)
Placebo Gel Vehicle4/64 (6.3%)0/64 (0%)4/64 (6.3%)
Most frequent other events
Showing 10 of 24
Most frequent other events
EventTest:Brimonidine 0.33% GelReference: Mirvaso 0.33% GelPlacebo Gel Vehicle
Burning sensationNervous system disorders4/1999/1990/64
Application site erythemaGeneral disorders5/1997/1990/64
FlushingVascular disorders6/1995/1991/64
HeadacheNervous system disorders4/1996/1990/64
Application site painGeneral disorders5/1992/1990/64
Application site pruritusGeneral disorders4/1992/1991/64
Back PainMusculoskeletal and connective tissue disorders0/1990/1991/64
Oropharyngeal PainRespiratory, thoracic and mediastinal disorders0/1990/1991/64
Application site warmthGeneral disorders2/1992/1990/64
Dry MouthGastrointestinal disorders1/1990/1990/64

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Test:Brimonidine 0.33% GelReference: Mirvaso 0.33% GelPlacebo Gel VehicleTotal
<=18 years0000
Between 18 and 65 years16316754384
>=65 years36321078
Sex: Female, Male
Sex: Female, Male(Participants)Test:Brimonidine 0.33% GelReference: Mirvaso 0.33% GelPlacebo Gel VehicleTotal
Female15115653360
Male484311102
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Test:Brimonidine 0.33% GelReference: Mirvaso 0.33% GelPlacebo Gel VehicleTotal
Hispanic or Latino606519144
Not Hispanic or Latino13913445318
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Test:Brimonidine 0.33% GelReference: Mirvaso 0.33% GelPlacebo Gel VehicleTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White19819864460
More than one race1102
Unknown or Not Reported0000
08

Study locations

16 sites
  • Investigator site 2
    Hot Springs, Arkansas 71913, United States
  • Investigator site 16
    Long Beach, California 90813, United States
  • Investigator site 5
    Miami, Florida 33015, United States
  • Investigator site 7
    Miami, Florida 33175, United States
  • Investigator site 8
    Miramar, Florida 33027, United States
  • Investigator site 6
    Ormond Beach, Florida 32174, United States
  • Investigator site 3
    Carmel, Indiana 46032, United States
  • Investigator site 9
    Louisville, Kentucky 40202, United States
  • Investigator site 14
    Fridley, Minnesota 55432, United States
  • Investigator site 15
    Henderson, Nevada 89052, United States
  • Investigator site 1
    Albuquerque, New Mexico 87106, United States
  • Investigator site 10
    High Point, North Carolina 27262, United States
  • Investigator site 11
    Beachwood, Ohio 44122, United States
  • Investigator site 4
    Nashville, Tennessee 37215, United States
  • Investigator site 13
    College Station, Texas 77845, United States
  • Investigator site 12
    Houston, Texas 77055, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2014, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2020, 5 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2014
First posted
Nov 13, 2014
Start
Jul 2014
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Results first posted
Jan 14, 2020
Last update
Jan 14, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02289352
Lead sponsor
Actavis Inc.
Responsible party
Sponsor
First posted
Nov 13, 2014
Start date
Jul 2014
Primary completion
Dec 2014
Completion
Dec 2014
Results posted
Jan 14, 2020
Last update
Jan 14, 2020

Study contacts

Nageshwar R Thudi, Ph.D.
study director · Actavis Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brimonidine

Start the discussion